43 results on '"HAN, C."'
Search Results
2. PCR93 Effect of Physicians’ Prescribing Choices of First- or Second-Line Tumor Necrosis Factor Inhibitor Biologics Versus Non-Tumor Necrosis Factor Inhibitor Biologic Therapies on Psoriatic Arthritis Patient-Reported Outcomes
3. PRO65 Engaging Patients in Drug Development for Regulatory and HTA Decisions: A Case Study in Patients with Hidradenitis Suppurativa
4. PNS66 Stated Importance Versus Actual Impact: An Evaluation of HTA Practices to Incorporate Patient Perspectives in Value Assessments
5. PSY69 - Development and Application of a Novel Patient-Reported Outcomes Instrument, The Psoriasis Symptoms and Signs Diary, Measuring Psoriasis Severity in Clinical Trials
6. PMS66 - Impact of Golimumab, An Anti-Tnfα Monoclonal Antibody, On Health Related Quality of Life (Hrqol) And Work Productivity In Patients With Active Psoriatic Arthritis: 24-Week Results of The Phase Iii Go Vibrant Trial
7. PMS67 - Work Productivity/Interference and General Health Status Improvements with Sirukumab, an Anti-Il-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs: Results from the Phase 3 Sirround-D Study
8. PGI23 - COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN’S DISEASE PATIENTS
9. PRM177 - Assessment of Content Equivalence and Usability Between the Paper and Electronic Versions of the Psoriasis Symptom and Sign Diary (Pssd) Among Subjects with Plaque Psoriasis
10. PSS33 - Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire
11. PGI27 - Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis
12. PMS19 - Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials
13. PMS54 - Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial
14. PMS20 Patients Reported Outcomes in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated With Golimumab: Sub-Analysis of Asia Population Enrolled in Multicentre Phase Iii Clinical Trials
15. PMS23 Health Related Quality of Life, Measured by the Short Form-36, of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis in an Urban Population of China
16. PMS49 Fatigue is an Independent Variable Predicting Physical Function and Das-28 Remission for Patients with Rheumatoid Arthritis Treated with Intravenously Administered Golimumab: Results from a Phase 3, Placebo Controlled Clinical Trial
17. PMS48 Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo-Controlled Trial
18. PMS52 Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Agaisnt Rheumatism: Analysis Based on Patient Reported Outcomes from 3 Phase III Clinical Trials of Golimumab
19. PMS66 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH NORMALIZED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE AND SIGNIFICANTLY IMPROVED PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB: TWO YEAR DATA FROM THE PHASE III GO-REVEAL CLINICAL TRIAL
20. PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES: A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS
21. PMS47 EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS METHOTREXATE OR METHOTREXATE ALONE
22. PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
23. PMS47 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY
24. PMS48 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3 STUDIES
25. PMS29 GOLIMUMAB SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED RESULTS FROM THREE PHASE 3 STUDIES
26. PSY5 IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
27. PMS12 USTEKINUMAB RESULTS: IN RAPID, SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PHYSICAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS: FROM A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL
28. PMS39 LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PRELIMINARY ANALYSIS USING MARKOV MODEL
29. PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL
30. PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
31. PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
32. PSS1 RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS
33. PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROMTHREE PHASE 3 STUDIES
34. PMS43 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED RESULTS FROMTHREE PHASE 3 STUDIES
35. MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY
36. PGI20 MAINTENANCE THERAPY WITH INFLIXIMAB REDUCES HOSPITALIZARON AND SURGERY IN CROHN'S DISEASE
37. PMS54 Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial
38. PGI27 Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis
39. PMS19 Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials
40. Assessment of Content Equivalence and Usability Between the Paper and Electronic Versions of the Psoriasis Symptom and Sign Diary (Pssd) Among Subjects with Plaque Psoriasis.
41. Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire.
42. Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials.
43. Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.